Fertility benefits company Progyny (NASDAQ: PGNY) met Wall Street’s revenue expectations in Q3 2026, with sales up 8.9% year on year to $341.3 million. The company expects next quarter’s revenue to be around $354.7 million, close to analysts’ estimates. Its non-GAAP profit of $0.52 per share was 2.2% above analysts’ consensus estimates.

Is now the time to buy PGNY? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Progyny’s third quarter results reflected continued growth in its core fertility benefits platform, supported by higher year-over-year sales volumes and margin expansion. Management attributed the performance to a record selling season, which added 1.3 million new covered lives and over 85 new clients, including large employers and prominent institutions. CEO Pete Anevski highlighted Progyny’s ability to deliver cost control and strong outcomes for clients despite broader medical inflation, noting, “Our results this season clearly speak to the robust appetite for a proven solution from employers.” While member engagement and utilization trends normalized after a temporary slowdown, the market’s muted reaction suggests some caution around the sustainability of recent gains and future growth levers.

Looking forward, Progyny’s guidance is shaped by expectations of stable engagement and the onboarding of new clients in the upcoming year. Management emphasized the diverse client base and robust sales pipeline, with Anevski stating, “We’re exiting the year with our strongest ever setup for the upcoming season ahead.” The company aims to maintain profitability while scaling investments in new offerings like Progyny Select, with CFO Mark Livingston reiterating a focus on balancing reinvestment and incremental margin expansion. The team also acknowledged that cost containment and consistent outcomes remain central to sustaining employer demand amid ongoing healthcare cost pressures.

Key insights from management’s remarks

Management pointed to a combination of record client additions, high retention rates, and operational efficiencies as primary drivers of performance, while also addressing emerging competitive and cost dynamics.

• Record new client wins: Progyny’s selling season added over 85 new clients and 1.3 million covered lives, spanning diverse industries and including several prestigious universities, a leading technology company, and major public sector accounts. Management cited strong demand for comprehensive fertility and women’s health benefits as a key motivator for employers.

• High client retention and upsell: The company reported near 100% client retention, with approximately 20% of the existing base expanding their benefits for the upcoming year. These expansions include consolidating additional women’s health services and increasing pharmacy program adoption, illustrating deepening relationships with current clients.

• Operational efficiency and margin leverage: Gross margin improved due to scale efficiencies and a reduction in stock-based compensation. CFO Mark Livingston emphasized that ongoing cost control and disciplined program management have allowed for both reinvestment and incremental profit growth, even as broader medical cost inflation remains elevated.

• Competitive landscape shifts: Management noted signs of rationalization in the market, with some competitors exiting or scaling back operations. Anevski asserted that Progyny’s differentiated solution and track record in cost containment have positioned it to capture share as employers seek proven partners.

• Selective product rollout: Progyny Select, the company’s fully insured offering, contributed minimally this season as intended, with management focused on building relationships and infrastructure for future scaling. Early feedback and market interest suggest potential for this product to become a meaningful growth driver over time.

Drivers of future performance

Progyny’s outlook is anchored by new client launches, continued upselling, and disciplined investment pacing, balanced by ongoing healthcare cost trends.

• Onboarding new clients: The majority of the 1.3 million new covered lives and over 85 clients are scheduled to launch next year, which management expects will be a primary engine for revenue growth. Anevski noted that the onboarding pipeline is diverse and includes both large and mid-sized employers, reducing concentration risks.

• Margin discipline amid investment: As elevated investment cycles begin to moderate, Progyny plans to balance reinvestment in platform enhancements and new offerings with incremental margin expansion. Livingston stated that efficiencies in care management delivery and cost containment will support stable or improving margins, even as the company continues to invest in future growth.

• Healthcare cost environment and utilization: Rising medical trend and cost pressures for employers remain an overarching theme. Management acknowledged that while demand for fertility benefits remains robust, client cost sensitivity could influence benefit adoption and utilization rates. Progyny’s ability to demonstrate value through outcomes and savings will be critical as clients weigh competing healthcare expenses.

Catalysts in upcoming quarters

In the coming quarters, our team will watch (1) the pace and success of onboarding new clients and covered lives from this year’s record selling season, (2) whether operational efficiencies and moderating investment cycles enable sustained margin improvement, and (3) continued client retention and upsell activity, particularly as healthcare cost pressures persist. Ongoing competitive shifts and adoption of new products like Progyny Select will also serve as indicators of market positioning and future growth potential.

Progyny currently trades at $29.60, down from $30.10 just before the earnings. Is there an opportunity in the stock? See for yourself in our full research report (it’s free).

High quality stocks for all market conditions

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.